EntryPoint Capital LLC Reduces Stock Holdings in Savara Inc (NASDAQ:SVRA)

EntryPoint Capital LLC lessened its holdings in shares of Savara Inc (NASDAQ:SVRA) by 65.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,887 shares of the company’s stock after selling 29,756 shares during the period. EntryPoint Capital LLC’s holdings in Savara were worth $79,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Jennison Associates LLC grew its position in Savara by 0.3% during the 1st quarter. Jennison Associates LLC now owns 8,841,971 shares of the company’s stock worth $44,033,000 after purchasing an additional 26,613 shares during the period. Vanguard Group Inc. grew its holdings in Savara by 2.5% during the first quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock worth $30,197,000 after acquiring an additional 148,673 shares during the period. Vivo Capital LLC raised its position in Savara by 9.1% during the fourth quarter. Vivo Capital LLC now owns 2,088,323 shares of the company’s stock valued at $9,815,000 after acquiring an additional 174,974 shares in the last quarter. Wellington Management Group LLP acquired a new position in Savara in the fourth quarter valued at approximately $9,683,000. Finally, Superstring Capital Management LP purchased a new stake in Savara in the 4th quarter worth approximately $3,827,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. HC Wainwright lifted their target price on shares of Savara from $6.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Evercore ISI decreased their price objective on shares of Savara from $10.00 to $7.00 and set an “outperform” rating for the company in a research report on Thursday, May 16th. Guggenheim increased their target price on shares of Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. Oppenheimer lifted their price target on Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a research note on Wednesday, June 26th. Finally, JMP Securities reiterated a “market outperform” rating and set a $8.00 price target on shares of Savara in a research report on Monday, May 6th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $11.00.

Savara Stock Performance

SVRA stock opened at $4.46 on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 14.90 and a quick ratio of 14.90. Savara Inc has a 52 week low of $3.12 and a 52 week high of $5.70. The firm has a 50-day simple moving average of $4.27 and a 200-day simple moving average of $4.64.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). On average, analysts predict that Savara Inc will post -0.41 EPS for the current year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.